Nine months ended

September 30,

2015

2014

Cash paid for interest

$

25,356

$

229,571

Series C Dividend payable in accrued expenses

$

--

$

--

Series D Dividend payable in accrued expenses

$

40,084

$

53,054

Non-Cash investing and financing transactions

Shares issued for consulting services

$

25,500

$

--

Conversion of unsecured debt to secured note payable

$

20,000

$

--

Financing the purchase of equipment under a

4 year loan agreement

$

--

$

49,204

Beneficial conversion feature on warrants issued

in conjunction with Series D preferred shares

$

--

$

24,279

Shares issued in acquisition of Dr. Pave

$

--

$

175,000

Deemed dividend related to warrant extension

$

--

$

26,832